Colorectal cancer is the most common cancer in Singapore. Read on to learn more
Approximately 1,200 new cases of colorectal cancer are diagnosed each year, making it the most common cancer in Singapore. The age-standardised incidences of colon and rectal cancer in Singapore are among the highest in the world. In particular, male Chinese Singaporeans have the dubious honour of having the highest age-standardised incidence of rectal cancer in the world!
Colorectal cancer is the most common cancer in Singapore. Male Chinese Singaporeans are, particularly at risk. Surgery is the mainstay of treatment for colorectal cancer. Early diagnosis improves the likelihood of a cure.
The majority of colorectal cancers arise from adenomatous polyps. Malignant transformation of adenomatous polyps (adenoma-carcinoma sequence) takes 5 to 10 years via multiple gene mutations. Adenomatous polyps are relatively asymptomatic. They are present in up to 25% of individuals at age 50 and the prevalence increases with age. Most polyps (90%) can be removed at colonoscopy, thereby precluding the need for surgery.
Thus, colorectal cancer has a detectable premalignant phase (adenoma) and a relatively long duration of malignant transformation. Mortality from colorectal cancer can be reduced by screening asymptomatic individuals for the presence of adenomas and early cancers.
Adenomatous polyps are largely asymptomatic.
The process of malignant transformation takes a relatively long time.
Screening for colorectal cancer:
Towards a Better State of Health
Screening should begin at age 50 years for individuals without any risk factors. In individuals with an increased risk, screening should begin earlier, before the age of 50, depending on the risk factor(s) present (Table shown below).
Onset (Age, Years)
A. Average Risk
Asymptomatic or family history limited to non-first degree relatives (screening tool alternatives in order of supporting evidence)
Every 5 to 10 years
B. High Risk
Colorectal cancer in the first degree relative age 60 years or younger or two or more first-degree relatives
10 years prior to the youngest case in the family or age 40 years, whichever is earlier
Every 5 Years
Colorectal cancer in the first degree relative over the age of 60 years
Every 10 Years
Personal history of colorectal polyps
1 to 3 years after polypectomy in the presence of high-risk features (>1cm, multiple, villous architecture); otherwise, 3 to 5 years after polypectomy for low risk polyps
Personal history of colorectal malignancy
One year after resection
Every 1 to 3 years
Personal history of ovarian or endometrial cancer
C. Very High Risk
A family history of familial adenomatous polyposis
Flexible sigmoidoscopy consider genetic counselling and testing
10 to 12 years (from puberty)
A family history of hereditary non-polyposis colorectal cancer
Colonoscopy, consider genetic counselling and testing
20 to 25 years
Every 1 to 2 years
Inflammatory bowel disease
From 15th year of diagnosis onwardsFrom 8th year of diagnosis onwards
Every 1 to 2 yearsEvery 1 to 2 years
Type 2 Screening Tests—by Age and Gender
For a screening test to be widely applicable, it must be inexpensive, reliable and acceptable. Various screening tests for colorectal cancer have been reported. Faecal occult blood testing (FOBT) is the only screening modality that has been shown in 3 large randomised trials to show a 33% reduction in colorectal cancer mortality. In light of this, it would be almost medically negligent not to offer FOBT screening for average-risk individuals age 50 and above. The other commonly employed screening test is colonoscopy.
Other screening alternatives include barium enema, sigmoidoscopy and CT colonography (virtual colonoscopy). However, current evidence suggests that these alternatives may not be as effective and reliable as FOBT or colonoscopy in large-scale population screening.
Immunochemical FOBTs detect human haemoglobin from partially digested blood in the stool. They are more sensitive and more specific than guaiac-based tests that were used in the past. Another advantage is that dietary restriction is not required in immunochemical testing.
Further evaluation will be recommended if any of the two stool samples provided by the patient is positive. In a large UK study, 12% and 23% of FOBT-positive individuals had cancer and adenomatous polyps respectively on colonoscopy. Cancers detected at screening were of an earlier stage than symptomatic ones (Duke’s A: 26% screened vs 11% in controls).
The main disadvantage of FOBT screening is its low sensitivity. An estimated 50% of cancers will be missed on each screening round. To enhance the pick-up rate, FOBT must be done annually.
How to collect a stool sample for FOBT:
Lay toilet paper in toilet bowl as shown on the right.
Reverse sitting position as shown below need be adopted to allow for stool to collect on the toilet paper to simplify collection of the stool sample for the FOBT test
Immunochemical FOBTs do not need dietary restriction. Individuals with positive FOBT require colonoscopy. Individuals with negative FOBT are tested annually.
Colonoscopy is the gold standard for complete large bowel evaluation. The main disadvantages are its higher cost, the need for full bowel preparation and sedation. There is also a small risk of bowel preparation. For high-risk patients e.g., individuals at risk of hereditary non-polyposis colorectal cancer, colonoscopy is the screening investigation of choice.
The main advantages are its high sensitivity and specificity and the long recommended screening interval of 10 years. The protective effect of colonoscopy is attributed to the ability to remove asymptomatic polyps before malignant transformation occurs.
Usually, bowel preparation takes 1 of 2 forms: high-volume (3-4 litres) polyethene glycol (PEG) or low-volume (90 ml) oral fleet. Oral fleet is contraindicated in patients with renal impairment due to its high phosphate content. For suitable patients, it is a more palatable option as it can be mixed with sweetened fluids. Patients taking oral fleet must be encouraged to drink plenty of water to decrease the likelihood of phosphate toxicity.
General advice to patients on bowel preparation for patients undergoing colonoscopy:
Oral medications which need to be stopped before colonoscopy:
Patients should go on a low fibre diet 3 days before colonoscopy, and avoid:
Foods allowed include:
Colonoscopy is the gold standard for large bowel evaluation. The screening interval for colonoscopy is 10 years. Bowel preparation with low-volume oral fleet is feasible in the absence of contraindications.
A barium enema is an alternative to colonoscopy for large bowel evaluation. However, bowel preparation is still needed and in some studies, the false negative rate is as high as 50%. Furthermore, colonoscopy may still be needed to rule out suspicious lesions on the enema. There are currently no population screening studies using barium enema.
Virtual colonoscopy is a new radiologic technique used to generate images of the colon and rectal wall. Bowel preparation is still needed and like barium enema, colonoscopy may be needed for ruling out suspicious lesions and for therapeutic polypectomy.
A recent meta-analysis suggests that overall polyp detection rate is woefully inadequate, making this new technique unsuitable for population screening.
Read these next:
This article was last reviewed on
Wednesday, May 26, 2021
The ABCs of Health Screening
The Importance of Sleep
How to Eat Right to Feel Right
Impact of Haze on health
Interesting Beliefs About Sneezing
How To Identify And Deal With Depression
View More Programmes
Screen for Life (SFL) is the national screening programme by the Health Promotion Board (HPB) that offers Singaporeans and Permanent Residents health screening recommendations based on age and gender.
Screen for Life (SFL) is a national screening programme that encourages Singapore Citizens and Permanent Residents to go for regular health screening and follow up.
National Diabetes Reference Materials
- An initiative under the War on Diabetes
Browse Live Healthy
One-stop access to all your health services and records.
In partnership with